J&J Procrit Gains Once-Weekly Dosing In Chemotherapy Patients
Executive Summary
Johnson & Johnson's Procrit (epoetin alfa) approval for once-weekly dosing in chemotherapy patients should relieve one of the marketing challenges it has had in facing Amgen's Aranesp (darbepoetin)